Spinal inflammation in the absence of sacroiliac joint inflammation on magnetic resonance imaging in patients with active nonradiographic axial spondyloarthritis
Der Heijde, D. V., Sieper, J., Maksymowych, W. P., Brown, Matthew A., Lambert, R. G. W., Rathmann, S. S., & Pangan, A. L. (2014) Spinal inflammation in the absence of sacroiliac joint inflammation on magnetic resonance imaging in patients with active nonradiographic axial spondyloarthritis. Arthritis and Rheumatology, 66(3), pp. 667-673.
To evaluate the presence of spinal inflammation with and without sacroiliac (SI) joint inflammation on magnetic resonance imaging (MRI) in patients with active nonradiographic axial spondyloarthritis (SpA), and to compare the disease characteristics of these subgroups.
ABILITY-1 is a multicenter, randomized, controlled trial of adalimumab versus placebo in patients with nonradiographic axial SpA classified using the Assessment of SpondyloArthritis international Society axial SpA criteria. Baseline MRIs were centrally scored independently by 2 readers using the Spondyloarthritis Research Consortium of Canada (SPARCC) method for the SI joints and the SPARCC 6-discovertebral unit method for the spine. Positive evidence of inflammation on MRI was defined as a SPARCC score of >2 for either the SI joints or the spine.
Among patients with baseline SPARCC scores, 40% had an SI joint score of >2 and 52% had a spine score of >2. Forty-nine percent of patients with baseline SI joint scores of <2, and 58% of those with baseline SI joint scores of >2, had a spine score of >2. Comparison of baseline disease characteristics by baseline SI joint and spine scores showed that a greater proportion of patients in the subgroup with a baseline SPARCC score of >2 for both SI joints and spine were male, and patients with spine and SI joint scores of <2 were younger and had shorter symptom duration. SPARCC spine scores correlated with baseline symptom duration, and SI joint scores correlated negatively with the baseline Bath Ankylosing Spondylitis Disease Activity Index, but neither correlated with the baseline Ankylosing Spondylitis Disease Activity Score, total back pain, the patient's global assessment of disease activity, the Bath Ankylosing Spondylitis Functional Index, morning stiffness, nocturnal pain, or C-reactive protein level.
Assessment by experienced readers showed that spinal inflammation on MRI might be observed in half of patients with nonradiographic axial SpA without SI joint inflammation.
Impact and interest:
Citation counts are sourced monthly from and citation databases.
These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.
Citations counts from theindexing service can be viewed at the linked Google Scholar™ search.
|Item Type:||Journal Article|
|Additional Information:||Cited By :9 Export Date: 21 September 2015 Correspondence Address: Pangan, A.L.; AbbVie Inc., North Chicago, IL, United States; email: firstname.lastname@example.org|
|Keywords:||adalimumab, C reactive protein, nonsteroid antiinflammatory agent, placebo, adult, aged, ankylosing spondylitis, Ankylosing Spondylitis Disease Activity Score, article, backache, Bath ankylosing spondylitis disease activity index, clinical assessment, clinical evaluation, clinical feature, controlled study, diagnostic test accuracy study, disease activity, female, human, major clinical study, male, middle aged, morning stiffness, multicenter study, myelitis, nuclear magnetic resonance imaging, pain, phase 3 clinical trial, predictive value, priority journal, protein blood level, randomized controlled trial, sacroiliac joint, sacroiliitis, scoring system, sensitivity and specificity, SPARCC score, spine, spondylarthritis, symptom, visual analog scale, young adult, Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Humans, Inflammation, Severity of Illness Index, Treatment Outcome|
|Deposited On:||25 Sep 2015 03:01|
|Last Modified:||18 Feb 2016 03:45|
Repository Staff Only: item control page